PROGRAMME SCHEDULE

Time shown in IST (Indian Standard Time)

DAY-1: Wednesday, 1^stSEPTEMBER, 2021

1:00 to 1:05 PM Prayer by Chaplain

1:05 to 1:15 PM Welcome and introductory remarks: Director, CMC / Principal, CMC / Director, inStem/ Head, CSCR

1:15 to 1:25 PM Remarks by Secretary, Department of Biotechnology, Ministry of Science and Technology, Govt. of India

KEY NOTE ADDRESS
Indian Time	Title	Speaker Name
1:30 to 2:30 PM	Gene therapy and gene editing for genetic diseases and cancer: a personal journey	Thierry Vanden Driessche Free University of Brussels & University of Leuven, Belgium

	Session-1: APPLICATIONS OF iPSC TECHNOLOGY
Indian Time	Title	Speaker Name
2.30 to 3:00 PM	iPSC based disease modelling of bone marrow failure diseases	RV Shaji Centre for Stem Cell Research, India
3:00 to 3:30 PM	The EBiSC iPSC bank for disease research	Rachel Steeg Fraunhofer UK Research Limited, Scotland, UK
3:30 to 4:00 PM	iPSC-based disease-modelling of Fanconi anaemia	Grant Rowe Boston Children’s Hospital and Dana-Farber Cancer Institute, Cambridge, USA
4:00 to 4:15 PM	Break
4:15 to 5:00 PM	Poster presentation/ Industry Symposium
	Session-2: TECHNOLOGY ADVANCES
Indian Time	Title	Speaker Name
5:00 to 5:30 PM	Genome editing for Sickle cell disease	Martin H. Steinberg Boston University and Boston Medical Centre, Boston
5:30 to 6:00 PM	Turning Genes into Medicines: Lessons Learned in the Pursuit of Gene Therapy for Haemophilia	Katherine A. High Asklepios BioPharmaceutical, Inc (AskBio), North Carolina, USA
6:00 to 6:30 PM	Preferential expansion of hematopoietic stem cells enhances gene-modified cell frequency for gene therapy	Saravanabhavan Thangavel Centre for Stem Cell Research, Vellore, India
6:30 to 6:45PM	Break

Session-3: GENE THERAPY
6:45 to 7:15 PM	Development of capsid- and genome-modified AAVrh74 vectors for gene therapy of muscular dystrophies	Arun Srivastava University of Florida College of Medicine, USA
7:15 to 7:45 PM	Validation of BCL11A as a Therapeutic Target in Sickle Cell Disease: Results from a First-in-Human Clinical Trial	David Williams Harvard Stem Cell Institute Bauer Building, Cambridge, USA
7:45 to 8:15 PM	Lentiviral vector-based gene therapy for Haemophilia A	Alok Srivastava Centre for Stem Cell Research, Vellore, India
	End of Day-1

Session-4: MANUFACTURING AND REGULATORY ASPECTS IN CELL AND GENE THERAPY

3:00 to 3:30 PM

Manufacturing and clinical application of mesenchymal stromal cells for diabetic complications

Timothy O’brien National University of Ireland, Galway, Ireland

3:30 to 4:00 PM

Manufacturing the vector and CAR-T cells in India – The nuts and bolts

Rahul Purwar Indian Institute of Technology Bombay, Mumbai, India

4:00 to 4:30 PM

Engineering Genetically Enhanced T cells for clinical applications

Bruce Levine Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

4:30 to 4:45 PM

Break

Session-5: CELL AND GENE THERAPY FOR OCULAR DISORDERS
4:45 to 5:15 PM	Regenerative medicine by epithelia: increasing the complexity	Graziella Pellegrini University of Modena and Reggio Emilia, Modena, Italy
5:15 to 5:45 PM	Gene augmentation strategies for corneal conditions	Arkasubhra Ghosh Narayana Netralaya, Bengaluru, India
5:45 to 6:15 PM	Advances in iPSC-derived outer retina tissue mimetic: Implications for translational approaches towards cell and gene-based therapy	Ruchira Singh University of Rochester, NewYork, USA

6:15 to 7:00 PM

Poster presentation/ Industry Symposium

*Session-6:* IMMUNE CELL THERAPY
7:00 to 7:30 PM	NK cell therapy in the treatment of liquid and solid tumors	Rizwan Romee Harvard Medical School, Dana Farber Cancer Institute, Boston, USA
7:30 to 8:00 PM	Developing genetically-engineered, clinically-scalable, γδ T Cells for the treatment of solid tumours and hematopoietic cancers of children	Trent Spencer Emory University, School of Medicine, USA
8:00 to 8:30 PM	The first indigenous CAR-T cells in India – From bench to clinic	Rahul Purwar Indian Institute of Technology Bombay, Mumbai, India
8:30 to 9:00 PM	Veto cells in haplo-transplantation and immune cell therapy	Yair Reisner MD Anderson Cancer Centre, Houston, TX, USA

End of Day-2

Session-7: CELL AND GENE THERAPY- INDUSTRY UPDATES
3:00 to 3:30 PM	Quality by Design: Reagents and Support for hPSC-Derived Cell and Gene Therapies	Kimberly Snyder Stem Cell Technologies, Vancouver, Canada
3:30 to 4:00 PM	Development of a scalable adeno-associated virus production process by transient transfection in suspension cells	Ann-Christin Magnusson Cytiva, Uppsala, Sweden
4:00 to 4:30 PM	Allogenic Cell and Gene therapy workflows with NK Cells	Mohan C. Vemuri Thermo Fisher Scientific Maryland, USA
4:30 to 4:45 PM	*Break*

Session-8: GENE EDITING
India Time	Title	Speaker Name
4:45 to 5:15 PM	Identification of novel HPFH-like mutations by CRISPR base editing that elevates the expression of fetal hemoglobin	Mohankumar Murugesan Centre for Stem Cell Research, Vellore, India
5:15 to 5:45 PM	Genome editing of hematopoietic stem cells	Pietro Genovese Harvard Medical School, Boston, USA
5:45 to 6:15 PM	Base editing of hematopoietic stem cells rescues sickle cell disease in mice	Jonathan Yen St. Jude Children’s Research Hospital, Memphis, USA
6:15 to 7:00 PM	Poster presentation/ Industry Symposium
Session-9: NON-VIRAL NUCLEIC ACID TRANSFER
India Time	Title	Speaker Name
7:00 to 7:30 PM	Nanoparticle-mediated gene therapy strategies for mitigating inflammatory bowel disease	Avinash Bajaj Regional Center for Biotechnology, New Delhi
7:30 to 8:00 PM	Development of Liver targeting lipid enabled nucleic acid delivery systems for therapeutic applications	Srujan Marepally Centre for Stem Cell Research, India
8:00 to 8:30 PM	Self-transcribing and replicating RNA based vaccine for SARS-CoV-2	Priya Prakash Karmali Arcturus Therapeutics, San Diego, USA
End of Day-3